Nikita Jeswani

Nikita Jeswani advises clients on the policy environment for defining value and recognizing medical advancements, the role of evidence in supporting patient access to clinically appropriate healthcare interventions, and on frameworks and tools used to support value-based care.

Nikita works with life sciences companies, trade associations, and patient advocacy groups to develop strategies around evidence generation and communication as well as quality improvement, comparative effectiveness research, and real-world evidence.

Prior to joining Avalere, Nikita interned at the Public Health Management Corporation in Philadelphia and at Privia Health, LLC, in Washington, DC.

Nikita has a BA from the University of Pennsylvania, where she studied economics, chemistry, and healthcare management, and an MBA from the University of Maryland Robert H. Smith School of Business.

Authored Content

Of the 329 oncology HTAs analyzed from the period 2013–2017, 29% resulted in positive recommendations without restrictions.

New research from Avalere Health finds that 86% of pharmaceutical companies would invest more in studies to support the development of healthcare economic information if provided additional guidance on their ability to use this evidence with external audiences.

Avalere released its latest white paper on patient-reported outcomes (PROs) today in collaboration with leaders from patient, payer, health information technology, product development and research communities.

New Avalere research shows market demand for real world evidence (RWE), but a lack of stakeholder consensus on how to define it.